These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16907931)

  • 21. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
    Liu PY; Lin LY; Lin HJ; Hsia CH; Hung YR; Yeh HI; Wu TC; Chen JY; Chien KL; Chen JW
    PLoS One; 2013; 8(10):e76298. PubMed ID: 24098467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
    Atalar E; Ozmen F; Haznedaroglu I; Açil T; Ozer N; Ovünç K; Aksöyek S; Kes S
    Int J Cardiol; 2002 Aug; 84(2-3):227-31. PubMed ID: 12127376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
    Radaelli A; Loardi C; Cazzaniga M; Balestri G; DeCarlini C; Cerrito MG; Cusa EN; Guerra L; Garducci S; Santo D; Menicanti L; Paolini G; Azzellino A; Lavitrano ML; Mancia G; Ferrari AU
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2750-5. PubMed ID: 17823365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
    Koshel'skaia OA; Vinnitskaia IV; Konko TIu; Kravchenko ES; Suslova TE; Karpov RS
    Kardiologiia; 2015; 55(3):67-74. PubMed ID: 26320293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
    Rodés-Cabau J; Tardif JC; Cossette M; Bertrand OF; Ibrahim R; Larose E; Grégoire J; L'allier PL; Guertin MC
    Am J Cardiol; 2009 Sep; 104(6):750-7. PubMed ID: 19733706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
    Deedwania P; Barter P; Carmena R; Fruchart JC; Grundy SM; Haffner S; Kastelein JJ; LaRosa JC; Schachner H; Shepherd J; Waters DD;
    Lancet; 2006 Sep; 368(9539):919-28. PubMed ID: 16962881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
    Arsenault BJ; Barter P; DeMicco DA; Bao W; Preston GM; LaRosa JC; Grundy SM; Deedwania P; Greten H; Wenger NK; Shepherd J; Waters DD; Kastelein JJ;
    J Am Coll Cardiol; 2011 Jan; 57(1):63-9. PubMed ID: 21185503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
    Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K
    Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy.
    Hirayama A; Saito S; Ueda Y; Takayama T; Honye J; Komatsu S; Yamaguchi O; Li Y; Yajima J; Nanto S; Takazawa K; Kodama K
    Circ J; 2009 Apr; 73(4):718-25. PubMed ID: 19225206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
    Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
    Patti G; Pasceri V; Nusca A; Di Sciascio G
    Ital Heart J Suppl; 2005 Sep; 6(9):553-60. PubMed ID: 16281714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A calcified left ventricular mass.
    Trenson S; de Ceuninck M
    Acta Cardiol; 2014 Jun; 69(3):316-8. PubMed ID: 25029880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.
    Pepine CJ; Rouleau JL; Annis K; Ducharme A; Ma P; Lenis J; Davies R; Thadani U; Chaitman B; Haber HE; Freedman SB; Pressler ML; Pitt B;
    J Am Coll Cardiol; 2003 Dec; 42(12):2049-59. PubMed ID: 14680725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial.
    Matsue Y; Matsumura A; Suzuki M; Hashimoto Y; Yoshida M
    Circ J; 2013; 77(7):1791-8. PubMed ID: 23603824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
    Nordøy A; Svensson B; Hansen JB
    J Thromb Haemost; 2003 Apr; 1(4):690-7. PubMed ID: 12871402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.